{
  "actions": [
    {
      "acted_at": "2001-03-15", 
      "committee": "Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned", 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2001-03-15", 
      "committee": "House Energy and Commerce", 
      "references": [], 
      "text": "Referred to House Energy and Commerce", 
      "type": "referral"
    }, 
    {
      "acted_at": "2001-03-15", 
      "committee": "House Judiciary", 
      "references": [], 
      "text": "Referred to House Judiciary", 
      "type": "referral"
    }, 
    {
      "acted_at": "2001-03-22", 
      "in_committee": "House Energy and Commerce", 
      "references": [], 
      "subcommittee": "Health", 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr1063-107", 
  "bill_type": "hr", 
  "committees": [
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }, 
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Judiciary", 
      "committee_id": "HSJU"
    }
  ], 
  "congress": "107", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2001-03-15", 
  "number": "1063", 
  "official_title": "To enhance competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding brand name drugs and generic drugs.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "Drug Competition Act of 2001", 
  "sponsor": {
    "district": "1", 
    "name": "Andrews, Robert E.", 
    "state": "NJ", 
    "thomas_id": "00021", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2001-03-15", 
  "subjects": [
    "Actions and defenses", 
    "Administrative procedure", 
    "Antitrust law", 
    "Commerce", 
    "Drug approvals", 
    "Drug industry", 
    "Federal Trade Commission", 
    "Fines (Penalties)", 
    "Generic drugs", 
    "Government operations and politics", 
    "Government paperwork", 
    "Health", 
    "Independent regulatory commissions", 
    "Injunctions", 
    "Law", 
    "Marketing", 
    "Pharmaceutical research", 
    "Research and development", 
    "Restrictive trade practices", 
    "Science, technology, communications"
  ], 
  "subjects_top_term": "Commerce", 
  "summary": {
    "as": "Introduced", 
    "date": "2001-03-15", 
    "text": "Drug Competition Act of 2001 - Requires brand name drug manufacturers and generic drug manufacturers to notify the Federal Trade Commission and the Attorney General of agreements regarding the sale or manufacture of generic drugs which could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Drug Competition Act of 2001", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To enhance competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding brand name drugs and generic drugs.", 
      "type": "official"
    }
  ], 
  "updated_at": "2013-07-14T18:57:21-04:00"
}